Diaceutics (LON:DXRX) Hits New 52-Week High – What’s Next?

Diaceutics PLC (LON:DXRX)’s stock price reached a new 52-week high on Wednesday. The stock traded as high as GBX 193 and last traded at GBX 185.86, with a volume of 1030922 shares trading hands. The stock had previously closed at GBX 186.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group restated a “buy” rating and set a GBX 215 price target on shares of Diaceutics in a report on Tuesday. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of GBX 215.

Diaceutics Trading Down 1.3%

The firm has a market cap of £161.70 million, a price-to-earnings ratio of 1,732.27 and a beta of 0.88. The company has a debt-to-equity ratio of 5.40, a quick ratio of 9.92 and a current ratio of 2.55. The company has a 50 day moving average price of GBX 148.17 and a 200 day moving average price of GBX 151.55.

Diaceutics (LON:DXRX) last issued its quarterly earnings data on Tuesday, September 22nd. The company reported GBX (3.27) earnings per share (EPS) for the quarter. Diaceutics had a negative return on equity of 0.68% and a negative net margin of 0.66%. On average, research analysts expect that Diaceutics PLC will post 1.0107919 earnings per share for the current year.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.